nach oben

Diabetologia

Erschienen in:

06.02.2021 | Review

Transforming type 1 diabetes: the next wave of innovation

verfasst von: Daniel J. Drucker

Erschienen in: Diabetologia | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

The discovery of insulin in 1921 enabled pharmaceutical production of animal insulins for the treatment of people with type 1 diabetes by 1922. The last several decades have witnessed enormous scientific progress in the therapy of type 1 diabetes, yet some developments have been incremental, and insulin is not a cure. Herein, I highlight key scientific advances potentially poised to improve the quality of life and treatment outcomes in type 1 diabetes. These innovations range from newer insulin analogues to the development of smart insulins, oral and weekly insulins, glucose sensors and closed-loop insulin-delivery devices, as well as strategies for durable human beta cell replacement coupled with selective immune manipulation to preserve beta cell function. Finally, progress in the prediction and prevention of type 1 diabetes highlights the ongoing challenges and potential for altering the natural history of the disease or eliminating type 1 diabetes altogether.

Graphical abstract

Nur mit Berechtigung zugänglich

Philis-Tsimikas A, Klonoff DC, Khunti K et al (2020) Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. Diabetologia 63(4):698–710. https://doi.org/10.1007/s00125-019-05080-9CrossRefPubMedPubMedCentral

Rosenstock J, Bajaj HS, Janez A et al (2020) Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med 383(22):2107–2116. https://doi.org/10.1056/NEJMoa2022474CrossRefPubMed

Drucker DJ (2020) Advances in oral peptide therapeutics. Nat Rev Drug Discov 19(4):277–289. https://doi.org/10.1038/s41573-019-0053-0CrossRefPubMed

Halberg IB, Lyby K, Wassermann K, Heise T, Zijlstra E, Plum-Morschel L (2019) Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. Lancet Diabetes Endocrinol 7(3):179–188. https://doi.org/10.1016/S2213-8587(18)30372-3CrossRefPubMed

Seaquist ER, Blonde L, McGill JB et al (2020) Hypoglycaemia is reduced with use of inhaled Technosphere® insulin relative to insulin aspart in type 1 diabetes mellitus. Diabet Med 37(5):752–759. https://doi.org/10.1111/dme.14202CrossRefPubMed

Abramson A, Caffarel-Salvador E, Khang M et al (2019) An ingestible self-orienting system for oral delivery of macromolecules. Science 363(6427):611–615. https://doi.org/10.1126/science.aau2277CrossRefPubMedPubMedCentral

Jarosinski MA, Dhayalan B, Rege N, Chatterjee D, Weiss MA (2021) ‘Smart’ insulin delivery technologies and intrinsic glucose-responsive analogues. Diabetologia (in press)

Boughton CK, Hovorka R (2021) New closed-loop insulin systems. Diabetologia. https://doi.org/10.1007/s00125-021-05391-w

Nathan DM (2021) Realising the long-term promise of insulin therapy: the DCCT/EDIC study. Diabetologia. https://doi.org/10.1007/s00125-021-05397-4

10.

Amiel SA (2021) The consequences of hypoglycaemia. Diabetologia. https://doi.org/10.1007/s00125-020-05366-3

11.

Keenan HA, Sun JK, Levine J et al (2010) Residual insulin production and pancreatic ss-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 59(11):2846–2853. https://doi.org/10.2337/db10-0676CrossRefPubMedPubMedCentral

12.

Ackeifi C, Wang P, Karakose E et al (2020) GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human beta cell regeneration. Sci Transl Med 12(53):eaaw9996. https://doi.org/10.1126/scitranslmed.aaw9996CrossRefPubMed

13.

Melton D (2021) The promise of stem cell-derived islet replacement therapy. Diabetologia. https://doi.org/10.1007/s00125-020-05367-2

14.

Bluestone JA, Tang Q (2020) Solving the puzzle of immune tolerance for beta-cell replacement therapy for type 1 diabetes. Cell Stem Cell 27(4):505–507. https://doi.org/10.1016/j.stem.2020.09.008CrossRefPubMed

15.

Liang Q, Monetti C, Shutova MV et al (2018) Linking a cell-division gene and a suicide gene to define and improve cell therapy safety. Nature 563(7733):701–704. https://doi.org/10.1038/s41586-018-0733-7CrossRefPubMed

16.

McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ (2020) Revisiting the complexity of GLP-1 action-from sites of synthesis to receptor activation. Endocr Rev. https://doi.org/10.1002/dev.22079

17.

Pollanen PM, Ryhanen SJ, Toppari J et al (2020) Dynamics of islet autoantibodies during prospective follow-up from birth to age 15 years. J Clin Endocrinol Metab 105(12):e4638–e4651. https://doi.org/10.1210/clinem/dgaa624CrossRefPubMedCentral

18.

Ismail HM, Cleves MA, Xu P et al (2020) The pathological evolution of glucose response curves during the progression to type 1 diabetes in the TrialNet Pathway to Prevention study. Diabetes Care 43(11):2668–2674. https://doi.org/10.2337/dc20-0701CrossRefPubMed

19.

Ferrat LA, Vehik K, Sharp SA et al (2020) A combined risk score enhances prediction of type 1 diabetes among susceptible children. Nat Med 26(8):1247–1255. https://doi.org/10.1038/s41591-020-0930-4CrossRefPubMedPubMedCentral

20.

Herold KC, Bundy BN, Long SA et al (2019) An anti-CD3 antibody, Teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 381(7):603–613. https://doi.org/10.1056/NEJMoa1902226CrossRefPubMedPubMedCentral

21.

Quattrin T, Haller MJ, Steck AK et al (2020) Golimumab and Beta-cell function in youth with new-onset type 1 diabetes. N Engl J Med 383(21):2007–2017. https://doi.org/10.1056/NEJMoa2006136CrossRefPubMed

22.

Marfil-Garza BA, Hefler J, Bermudez De Leon M, Pawlick R, Dadheech N, Shapiro AMJ (2020) Progress in translational regulatory T cell therapies for type 1 diabetes and islet transplantation. Endocr Rev. https://doi.org/10.1210/endrev/bnaa028

23.

Beran D, Lazo-Porras M, Mba CM, Mbanya JC (2021) A global perspective on the issue of access to insulin. Diabetologia. https://doi.org/10.1007/s00125-020-05375-2

24.

Chan JCN, Lim LL, Wareham NJ et al (2020) The Lancet commission on diabetes: using data to transform diabetes care and patient lives. Lancet 396(10267):2019–2082. https://doi.org/10.1016/S0140-6736(20)32374-6

25.

World Health Organization (2020). The WHO Global Diabetes Compact: uniting around a common agenda for diabetes. Available from: www.who.int/docs/default-source/world-diabetes-day/global-diabetes-compact-final.pdf Accessed 13 January 2021

26.

Banting FG (1925) Frederick G. Banting Nobel Lecture. Available from: www.nobelprize.org/prizes/medicine/1923/banting/lecture/. Accessed: 13 January 2021

Titel: Transforming type 1 diabetes: the next wave of innovation
verfasst von: Daniel J. Drucker
Publikationsdatum: 06.02.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 5/2021
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-021-05396-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Transforming type 1 diabetes: the next wave of innovation

Abstract

Graphical abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Update Innere Medizin

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Graphical abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2021

Realising the long-term promise of insulin therapy: the DCCT/EDIC study

Current and future therapies for type 1 diabetes

Retinal venular tortuosity and fractal dimension predict incident retinopathy in adults with type 2 diabetes: the Edinburgh Type 2 Diabetes Study

Heterogeneity in insulin-stimulated glucose uptake among different muscle groups in healthy lean people and people with obesity

Potential diabetes overtreatment and risk of adverse events among older adults in Ontario: a population-based study

Defining the underlying defect in insulin action in type 2 diabetes

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Update Innere Medizin